Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
Maccaroni E, Giampieri R, Lenci E, Scortichini L, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Ambrosini E, Berardi R. Maccaroni E, et al. Among authors: lenci e. World J Clin Oncol. 2021 Jul 24;12(7):565-580. doi: 10.5306/wjco.v12.i7.565. World J Clin Oncol. 2021. PMID: 34367929 Free PMC article. Review.
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis.
Cantini L, Merloni F, Rinaldi S, Lenci E, Marcantognini G, Meletani T, Fiordoliva I, Morgese F, Torniai M, Ricci G, Giampieri R, Berardi R. Cantini L, et al. Among authors: lenci e. Crit Rev Oncol Hematol. 2020 Jul;151:102974. doi: 10.1016/j.critrevonc.2020.102974. Epub 2020 May 4. Crit Rev Oncol Hematol. 2020. PMID: 32416348
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, Nicolardi L, Caglio A, Aerts S, Cortellini A, Ficorella C, Chiari R, Di Maio M, Dingemans AC, Aerts JGJV, Berardi R. Lenci E, et al. J Clin Med. 2021 Mar 2;10(5):1005. doi: 10.3390/jcm10051005. J Clin Med. 2021. PMID: 33801320 Free PMC article.
The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience.
Pistelli M, Natalucci V, Scortichini L, Agostinelli V, Lenci E, Crocetti S, Merloni F, Bastianelli L, Taus M, Fumelli D, Giulietti G, Cola C, Capecci M, Serrani R, Ceravolo MG, Ricci M, Nicolai A, Barbieri E, Nicolai G, Ballatore Z, Savini A, Berardi R. Pistelli M, et al. Among authors: lenci e. Cancers (Basel). 2021 Nov 4;13(21):5539. doi: 10.3390/cancers13215539. Cancers (Basel). 2021. PMID: 34771702 Free PMC article.
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.
Lenci E, Marcantognini G, Cognigni V, Lupi A, Rinaldi S, Cantini L, Fiordoliva I, Carloni AL, Rocchi M, Zuccatosta L, Gasparini S, Berardi R. Lenci E, et al. Explor Target Antitumor Ther. 2021;2(3):227-239. doi: 10.37349/etat.2021.00043. Epub 2021 Jun 28. Explor Target Antitumor Ther. 2021. PMID: 36046436 Free PMC article.
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type.
Maccaroni E, Lenci E, Agostinelli V, Cognigni V, Giampieri R, Mazzanti P, Di Pietro Paolo M, Bianchi F, Brugiati C, Belvederesi L, Pagliaretta S, Mandolesi A, Scarpelli M, Murrone A, Morgese F, Ballatore Z, Berardi R. Maccaroni E, et al. Among authors: lenci e. Explor Target Antitumor Ther. 2021;2(3):240-248. doi: 10.37349/etat.2021.00044. Epub 2021 Jun 28. Explor Target Antitumor Ther. 2021. PMID: 36046437 Free PMC article.
63 results